AU2014228460B2 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions Download PDF

Info

Publication number
AU2014228460B2
AU2014228460B2 AU2014228460A AU2014228460A AU2014228460B2 AU 2014228460 B2 AU2014228460 B2 AU 2014228460B2 AU 2014228460 A AU2014228460 A AU 2014228460A AU 2014228460 A AU2014228460 A AU 2014228460A AU 2014228460 B2 AU2014228460 B2 AU 2014228460B2
Authority
AU
Australia
Prior art keywords
arg
phe
cys
peptide
excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014228460A
Other languages
English (en)
Other versions
AU2014228460A1 (en
Inventor
Bart Henderson
Shubh Sharma
Leonardus H. T. Van Der Ploeg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhythm Pharmaceuticals Inc
Original Assignee
Rhythm Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50732290&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014228460(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhythm Pharmaceuticals Inc filed Critical Rhythm Pharmaceuticals Inc
Publication of AU2014228460A1 publication Critical patent/AU2014228460A1/en
Assigned to RHYTHM PHARMACEUTICALS, INC. reassignment RHYTHM PHARMACEUTICALS, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: RHYTHM METABOLIC, INC.
Application granted granted Critical
Publication of AU2014228460B2 publication Critical patent/AU2014228460B2/en
Priority to AU2019200101A priority Critical patent/AU2019200101B2/en
Priority to AU2021202699A priority patent/AU2021202699A1/en
Priority to AU2023204625A priority patent/AU2023204625A1/en
Priority to AU2025213562A priority patent/AU2025213562A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2014228460A 2013-03-15 2014-03-14 Pharmaceutical compositions Active AU2014228460B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2019200101A AU2019200101B2 (en) 2013-03-15 2019-01-08 Pharmaceutical Compositions
AU2021202699A AU2021202699A1 (en) 2013-03-15 2021-04-30 Pharmaceutical compositions
AU2023204625A AU2023204625A1 (en) 2013-03-15 2023-07-12 Pharmaceutical compositions
AU2025213562A AU2025213562A1 (en) 2013-03-15 2025-08-05 Pharmaceutical compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361792440P 2013-03-15 2013-03-15
US61/792,440 2013-03-15
PCT/US2014/029421 WO2014144842A2 (en) 2013-03-15 2014-03-14 Pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019200101A Division AU2019200101B2 (en) 2013-03-15 2019-01-08 Pharmaceutical Compositions

Publications (2)

Publication Number Publication Date
AU2014228460A1 AU2014228460A1 (en) 2015-10-01
AU2014228460B2 true AU2014228460B2 (en) 2018-11-01

Family

ID=50732290

Family Applications (5)

Application Number Title Priority Date Filing Date
AU2014228460A Active AU2014228460B2 (en) 2013-03-15 2014-03-14 Pharmaceutical compositions
AU2019200101A Active AU2019200101B2 (en) 2013-03-15 2019-01-08 Pharmaceutical Compositions
AU2021202699A Abandoned AU2021202699A1 (en) 2013-03-15 2021-04-30 Pharmaceutical compositions
AU2023204625A Abandoned AU2023204625A1 (en) 2013-03-15 2023-07-12 Pharmaceutical compositions
AU2025213562A Pending AU2025213562A1 (en) 2013-03-15 2025-08-05 Pharmaceutical compositions

Family Applications After (4)

Application Number Title Priority Date Filing Date
AU2019200101A Active AU2019200101B2 (en) 2013-03-15 2019-01-08 Pharmaceutical Compositions
AU2021202699A Abandoned AU2021202699A1 (en) 2013-03-15 2021-04-30 Pharmaceutical compositions
AU2023204625A Abandoned AU2023204625A1 (en) 2013-03-15 2023-07-12 Pharmaceutical compositions
AU2025213562A Pending AU2025213562A1 (en) 2013-03-15 2025-08-05 Pharmaceutical compositions

Country Status (18)

Country Link
US (3) US11129869B2 (enExample)
EP (2) EP3778623A1 (enExample)
JP (4) JP6538025B2 (enExample)
KR (1) KR102378943B1 (enExample)
CN (3) CN105518021A (enExample)
AU (5) AU2014228460B2 (enExample)
BR (1) BR112015023409B1 (enExample)
CA (2) CA3209602A1 (enExample)
DK (1) DK2970389T3 (enExample)
ES (1) ES2825076T3 (enExample)
FR (1) FR21C1059I2 (enExample)
IL (2) IL288961B1 (enExample)
NL (1) NL301149I2 (enExample)
NO (1) NO2021051I1 (enExample)
PL (1) PL2970389T3 (enExample)
PT (1) PT2970389T (enExample)
RU (1) RU2690377C2 (enExample)
WO (1) WO2014144842A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100734T1 (it) 2011-12-29 2022-03-21 Rhythm Pharmaceuticals Inc Metodo di trattamento di disturbi associati al recettore di melanocortina 4 in portatori eterozigoti
JP6622690B2 (ja) 2013-03-15 2019-12-18 リズム・ファーマシューティカルズ・インコーポレイテッド ペプチド組成物
JP6538025B2 (ja) * 2013-03-15 2019-07-03 リズム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物
US10835549B2 (en) 2013-04-11 2020-11-17 Vanderbilt University Polyplexes
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
MX2018003983A (es) * 2015-09-30 2018-11-09 Rhythm Pharmaceuticals Inc Metodo de tratamiento de trastornos asociados a la via del receptor de melanocortina-4.
JP6701572B2 (ja) * 2016-07-05 2020-05-27 株式会社リコー インク、収容容器、画像形成方法及び画像形成装置
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
US20200223889A1 (en) 2017-03-15 2020-07-16 Novo Nordisk A/S Bicyclic Compounds Capable of Binding to Melanocortin 4 Receptor
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
WO2019099735A1 (en) * 2017-11-15 2019-05-23 Rhythm Pharmaceuticals, Inc. Sustained release peptide formulations
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
KR102087634B1 (ko) * 2018-10-11 2020-03-11 (주)바이텍 항비만용 조성물
SG11202106847SA (en) * 2019-01-04 2021-07-29 Kineta Chronic Pain Llc Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
CN111718408A (zh) * 2020-07-06 2020-09-29 成都圣诺生物制药有限公司 一种Setmelanotide的制备方法
JP2024532294A (ja) * 2021-08-24 2024-09-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｃ４ｒアゴニストペプチド
WO2023080712A1 (ko) * 2021-11-05 2023-05-11 ㈜아이엠디팜 신규한 서방성 지질 전구 제제 및 이를 포함하는 서방성 주사용 약학 조성물
WO2023247999A1 (en) * 2022-06-24 2023-12-28 Mainline Biosciences (Shanghai) Co., Ltd. Peptidic pain modulators and methods for producing and using the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026251A1 (en) * 1993-05-07 1994-11-24 Sequus Pharmaceuticals, Inc. Subcutaneous liposome delivery method
WO2007022254A2 (en) * 2005-08-15 2007-02-22 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
WO2009158415A1 (en) * 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
WO2012172433A2 (en) * 2011-06-14 2012-12-20 Ipsen Pharma S.A.S. A sustained-release composition containing peptides as active ingredient

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
CA2433335C (en) * 2000-12-29 2010-04-20 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
AU2002322466B2 (en) * 2001-07-11 2007-08-30 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
FR2851563B1 (fr) 2003-02-26 2005-04-22 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
FR2852957B1 (fr) 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
EA200600055A1 (ru) * 2003-06-19 2006-08-25 Эли Лилли Энд Компани Агонисты рецептора меланокортина 4 (мк4 ) и их применение
FR2862971B1 (fr) 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
KR100638041B1 (ko) 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
FR2872165B1 (fr) 2004-06-24 2006-09-22 Sod Conseils Rech Applic Nouveaux derives de pyrimido-benzimidazole
ES2663916T3 (es) 2005-07-08 2018-04-17 Ipsen Pharma Ligandos de los receptores de la melanocortina
EP1915168A4 (en) 2005-07-08 2010-03-31 Ipsen Pharma LIGANDS OF MELANOCORTIN RECEPTORS
CA2689016C (en) 2007-05-25 2014-08-12 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
EP2167112A4 (en) 2007-06-15 2012-01-25 Ipsen Pharma Sas CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS
EP2979703B1 (en) 2007-11-05 2018-07-18 Ipsen Pharma S.A.S. Use of melanocortins to treat insulin sensitivity
AR072072A1 (es) * 2008-06-09 2010-08-04 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina para el tratamiento de la obesidad / 669
CN101439182B (zh) * 2008-12-18 2012-02-01 北京大学 一种生长抑素受体介导的肿瘤靶向药物组合物
BRPI1009644B1 (pt) * 2009-06-08 2022-02-08 Palatin Technologies, Inc Peptídeo cíclico ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso da composição farmacêutica
UY32690A (es) * 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
MX2012001513A (es) 2009-08-05 2012-05-22 Ipsen Pharma Sas Uso de melanocortinas para tratar la dislipidemia.
WO2011060355A1 (en) 2009-11-16 2011-05-19 Ipsen Pharma S.A.S Process for the synthesis of ac-arg-cyclo(cys-d-ala-his-d-phe-arg-trp-cys)-nh2
JP5486690B2 (ja) 2009-11-16 2014-05-07 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンドの医薬組成物
JP2013046596A (ja) 2011-08-29 2013-03-07 Alpha-Nano-Medica Co Ltd 新規な複合体、それを含有する医薬及び癌の治療方法
WO2013033838A1 (en) 2011-09-09 2013-03-14 Pharmagap Inc. Liposomal formulations of cationic peptides and uses thereof
EP2705835A1 (en) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
JP6622690B2 (ja) * 2013-03-15 2019-12-18 リズム・ファーマシューティカルズ・インコーポレイテッド ペプチド組成物
JP6538025B2 (ja) 2013-03-15 2019-07-03 リズム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026251A1 (en) * 1993-05-07 1994-11-24 Sequus Pharmaceuticals, Inc. Subcutaneous liposome delivery method
WO2007022254A2 (en) * 2005-08-15 2007-02-22 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
WO2009158415A1 (en) * 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
WO2012172433A2 (en) * 2011-06-14 2012-12-20 Ipsen Pharma S.A.S. A sustained-release composition containing peptides as active ingredient

Also Published As

Publication number Publication date
CA2906782C (en) 2023-10-03
IL241378B (en) 2022-01-01
HK1220702A1 (en) 2017-05-12
PL2970389T3 (pl) 2021-03-08
NO2021051I1 (no) 2024-08-05
FR21C1059I1 (fr) 2022-01-21
AU2014228460A1 (en) 2015-10-01
US20220160818A1 (en) 2022-05-26
IL288961B1 (en) 2026-05-01
JP2025004067A (ja) 2025-01-14
BR112015023409A8 (pt) 2019-12-03
NL301149I2 (nl) 2022-11-24
US11129869B2 (en) 2021-09-28
EP3778623A1 (en) 2021-02-17
CN105518021A (zh) 2016-04-20
AU2021202699A1 (en) 2021-05-27
IL241378A0 (en) 2015-11-30
BR112015023409B1 (pt) 2023-11-28
JP2016516062A (ja) 2016-06-02
FR21C1059I2 (fr) 2022-12-02
RU2690377C2 (ru) 2019-06-03
US12285460B2 (en) 2025-04-29
CA3209602A1 (en) 2014-09-18
US20160022764A1 (en) 2016-01-28
WO2014144842A2 (en) 2014-09-18
BR112015023409A2 (pt) 2017-07-18
KR102378943B1 (ko) 2022-03-25
CA2906782A1 (en) 2014-09-18
EP2970389A2 (en) 2016-01-20
IL288961A (en) 2022-02-01
AU2019200101B2 (en) 2021-02-04
JP2019189619A (ja) 2019-10-31
PT2970389T (pt) 2020-10-21
RU2019116003A (ru) 2019-07-17
DK2970389T3 (da) 2020-10-26
EP2970389B1 (en) 2020-08-19
CN115957296A (zh) 2023-04-14
NL301149I1 (enExample) 2021-12-08
AU2023204625A1 (en) 2023-08-03
JP2022065117A (ja) 2022-04-26
RU2015143965A (ru) 2017-04-24
AU2025213562A1 (en) 2025-08-21
KR20160020405A (ko) 2016-02-23
ES2825076T3 (es) 2021-05-14
AU2019200101A1 (en) 2019-01-31
WO2014144842A3 (en) 2015-04-09
CN115957297A (zh) 2023-04-14
JP6538025B2 (ja) 2019-07-03
US20260053885A1 (en) 2026-02-26

Similar Documents

Publication Publication Date Title
US12285460B2 (en) Pharmaceutical compositions
US12077612B2 (en) Peptide compositions
HK40046859A (en) Pharmaceutical compositions
RU2844779C2 (ru) Фармацевтические композиции
HK1220702B (en) Pharmaceutical compositions
HK40006194A (en) Peptide compositions
HK1220697B (en) Peptide compositions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)